Such novel findings accentuate the fact that annexin A2 might be considered a therapeutic target antigen for ovarian cancer, as well as breast cancer; however, broader preclinical and substantiated clinical evidence is required before confidently classifying this antigen as a potential target. Here, ANXA2 is linked to ovarian cancer.